CA2882687A1 - Methods for prevention and treatment of preeclampsia - Google Patents
Methods for prevention and treatment of preeclampsia Download PDFInfo
- Publication number
- CA2882687A1 CA2882687A1 CA2882687A CA2882687A CA2882687A1 CA 2882687 A1 CA2882687 A1 CA 2882687A1 CA 2882687 A CA2882687 A CA 2882687A CA 2882687 A CA2882687 A CA 2882687A CA 2882687 A1 CA2882687 A1 CA 2882687A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- stromal cells
- adherent
- manufacture
- article
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000011461 pre-eclampsia Diseases 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 48
- 238000011282 treatment Methods 0.000 title claims description 49
- 230000002265 prevention Effects 0.000 title claims description 5
- 230000001464 adherent effect Effects 0.000 claims abstract description 134
- 210000002536 stromal cell Anatomy 0.000 claims abstract description 90
- 238000004519 manufacturing process Methods 0.000 claims abstract description 33
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 32
- 210000005059 placental tissue Anatomy 0.000 claims abstract description 30
- 208000002296 eclampsia Diseases 0.000 claims abstract description 24
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 17
- 239000005022 packaging material Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 191
- 230000035935 pregnancy Effects 0.000 claims description 64
- 230000008774 maternal effect Effects 0.000 claims description 22
- 230000001965 increasing effect Effects 0.000 claims description 20
- 238000012258 culturing Methods 0.000 claims description 17
- 206010020772 Hypertension Diseases 0.000 claims description 15
- 210000002966 serum Anatomy 0.000 claims description 13
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 11
- 102100035194 Placenta growth factor Human genes 0.000 claims description 11
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 10
- 230000008694 endothelial dysfunction Effects 0.000 claims description 10
- 210000003754 fetus Anatomy 0.000 claims description 9
- 230000014509 gene expression Effects 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 230000010412 perfusion Effects 0.000 claims description 9
- 102100037241 Endoglin Human genes 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 108010036395 Endoglin Proteins 0.000 claims description 4
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 4
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 230000028742 placenta development Effects 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 201000005665 thrombophilia Diseases 0.000 claims description 4
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 3
- 206010004272 Benign hydatidiform mole Diseases 0.000 claims description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 3
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 3
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 3
- 208000006937 Hydatidiform mole Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 3
- 208000025972 Maternal Obesity Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 208000020060 Increased inflammatory response Diseases 0.000 claims description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 101
- 108010072210 Cyclophilin C Proteins 0.000 description 59
- 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 description 59
- 239000004698 Polyethylene Substances 0.000 description 55
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 38
- 230000003169 placental effect Effects 0.000 description 22
- 239000003981 vehicle Substances 0.000 description 20
- 210000002826 placenta Anatomy 0.000 description 18
- 238000010255 intramuscular injection Methods 0.000 description 16
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 12
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000001605 fetal effect Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 201000001474 proteinuria Diseases 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000011321 prophylaxis Methods 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- 208000001951 Fetal Death Diseases 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 7
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 7
- 238000002659 cell therapy Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000036266 weeks of gestation Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- -1 PDGF Proteins 0.000 description 5
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 5
- 206010041660 Splenomegaly Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000001668 ameliorated effect Effects 0.000 description 5
- 230000001772 anti-angiogenic effect Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 201000005624 HELLP Syndrome Diseases 0.000 description 4
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 239000007758 minimum essential medium Substances 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 230000009984 peri-natal effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000001023 pro-angiogenic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010070538 Gestational hypertension Diseases 0.000 description 3
- 208000000091 Maternal Death Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 229920001432 poly(L-lactide) Polymers 0.000 description 3
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940083618 sodium nitroprusside Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008718 systemic inflammatory response Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
- 206010068051 Chimerism Diseases 0.000 description 2
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101001078082 Homo sapiens Reticulocalbin-3 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- 206010034576 Peripheral ischaemia Diseases 0.000 description 2
- 102100025343 Reticulocalbin-3 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000002818 limb ischemia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 201000005608 severe pre-eclampsia Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000008347 uteroplacental blood flow Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 1
- 102100036630 60S ribosomal protein L7a Human genes 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000212977 Andira Species 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 241001416153 Bos grunniens Species 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102300038161 CD44 antigen isoform 2 Human genes 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 101710092112 Calponin-1 Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000030275 Chondronectin Diseases 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100033269 Cyclin-dependent kinase inhibitor 1C Human genes 0.000 description 1
- 101710153652 Cyclin-dependent kinase inhibitor 1C Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102100031334 Elongation factor 2 Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101710139370 Eukaryotic translation elongation factor 2 Proteins 0.000 description 1
- 241001659457 Exophiala equina Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 description 1
- 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000853243 Homo sapiens 60S ribosomal protein L7a Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101001095368 Homo sapiens Serine/threonine-protein phosphatase PP1-gamma catalytic subunit Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036557 Pregnancy associated hypertension Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 102100037761 Serine/threonine-protein phosphatase PP1-gamma catalytic subunit Human genes 0.000 description 1
- 206010041092 Small for dates baby Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- AGQFLEFSRLZALV-KQYNXXCUSA-N [9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-iminopurin-3-yl]phosphonic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N(C=NC2=N)P(O)(O)=O)=C2N=C1 AGQFLEFSRLZALV-KQYNXXCUSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000013030 cryopreservent agent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000005151 decidua basalis Anatomy 0.000 description 1
- 210000005150 decidua parietalis Anatomy 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 102000043667 human chondronectin Human genes 0.000 description 1
- 108700020610 human chondronectin Proteins 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008375 physiological alteration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000008741 proinflammatory signaling process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008601 sVEGFR Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261696442P | 2012-09-04 | 2012-09-04 | |
| US61/696,442 | 2012-09-04 | ||
| US201361815760P | 2013-04-25 | 2013-04-25 | |
| US61/815,760 | 2013-04-25 | ||
| US201361825037P | 2013-05-19 | 2013-05-19 | |
| US61/825,037 | 2013-05-19 | ||
| PCT/IB2013/058186 WO2014037863A1 (en) | 2012-09-04 | 2013-08-31 | Methods for prevention and treatment of preeclampsia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2882687A1 true CA2882687A1 (en) | 2014-03-13 |
Family
ID=49354724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2882687A Abandoned CA2882687A1 (en) | 2012-09-04 | 2013-08-31 | Methods for prevention and treatment of preeclampsia |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9950014B2 (enExample) |
| EP (1) | EP2892542B1 (enExample) |
| JP (1) | JP6371286B2 (enExample) |
| KR (1) | KR101921787B1 (enExample) |
| CN (1) | CN104768559B (enExample) |
| AU (1) | AU2013311289B2 (enExample) |
| CA (1) | CA2882687A1 (enExample) |
| HK (1) | HK1212239A1 (enExample) |
| IL (1) | IL237528B (enExample) |
| SG (2) | SG10201700435XA (enExample) |
| WO (1) | WO2014037863A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116747212A (zh) * | 2023-07-04 | 2023-09-15 | 山东省妇幼保健院 | 6-姜酚在制备治疗先兆子痫药物中的应用 |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101738323B1 (ko) | 2007-09-19 | 2017-05-19 | 플루리스템 리미티드 | 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도 |
| EP2303293A1 (en) | 2008-05-27 | 2011-04-06 | Pluristem Ltd. | Methods of treating inflammatory colon diseases |
| SG190659A1 (en) | 2008-09-02 | 2013-06-28 | Pluristem Ltd | Adherent cells from placenta tissue and use thereof in therapy |
| ES2553712T3 (es) | 2009-11-30 | 2015-12-11 | Pluristem Ltd. | Células adherentes de la placenta y uso de las mismas en el tratamiento de enfermedad |
| WO2011147967A1 (en) | 2010-05-27 | 2011-12-01 | Georg Duda | Skeletal muscle regeneration using mesenchymal stem cells |
| US8895291B2 (en) | 2010-10-08 | 2014-11-25 | Terumo Bct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| WO2012127320A1 (en) | 2011-03-22 | 2012-09-27 | Pluristem Ltd. | Methods for treating radiation or chemical injury |
| US9657266B2 (en) | 2011-04-15 | 2017-05-23 | Pluristem Ltd. | Methods and systems for harvesting cells |
| WO2014098960A2 (en) * | 2012-05-16 | 2014-06-26 | The Johns Hopkins University | Stem cells as an individualized maternal therapy for prevention of prematurity |
| SI2739720T1 (sl) | 2012-09-06 | 2015-04-30 | Pluristem Ltd. | Naprave in postopki za gojenje celic |
| JP6612227B2 (ja) | 2013-11-16 | 2019-11-27 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
| WO2015132729A1 (en) | 2014-03-04 | 2015-09-11 | Pluristem Ltd. | Systems and methods for growing and harvesting cells |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| WO2017205667A1 (en) | 2016-05-25 | 2017-11-30 | Terumo Bct, Inc. | Cell expansion |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US20190224244A1 (en) * | 2016-07-11 | 2019-07-25 | Bonus Therapeutics Ltd. | Cell compositions for tissue regeneration |
| EA201991371A1 (ru) * | 2016-12-05 | 2019-12-30 | Селулэрити, Инк. | Лечение лимфедемы и связанных состояний с использованием плацентарных адгезивных клеток |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| WO2018184028A2 (en) | 2017-03-31 | 2018-10-04 | Terumo Bct, Inc. | Cell expansion |
| KR102435297B1 (ko) * | 2020-07-21 | 2022-08-22 | 부산대학교 산학협력단 | 임신중독증 조기진단용 바이오마커 조성물 및 이를 이용한 진단방법 |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| CN114195875B (zh) * | 2021-06-17 | 2022-07-12 | 南京市妇幼保健院 | 一种胎盘来源内源性多肽及其应用 |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5902741A (en) | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
| US5629186A (en) | 1994-04-28 | 1997-05-13 | Lockheed Martin Corporation | Porous matrix and method of its production |
| US6132463A (en) | 1995-05-19 | 2000-10-17 | Etex Corporation | Cell seeding of ceramic compositions |
| EP1064353B1 (en) | 1998-03-18 | 2002-11-06 | Massachusetts Institute Of Technology | Vascularized perfused microtissue/micro-organ arrays |
| US6153432A (en) | 1999-01-29 | 2000-11-28 | Zen-Bio, Inc | Methods for the differentiation of human preadipocytes into adipocytes |
| WO2000046349A1 (en) | 1999-02-04 | 2000-08-10 | Technion Research & Development Foundation Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
| PT1261694E (pt) | 2000-02-26 | 2008-04-03 | Artecel Inc | Células estaminais pluripotentes produzidas a partir de células estromais derivadas de tecido adiposo e suas utilizações. |
| EP2198876B1 (en) * | 2003-10-24 | 2012-12-05 | Nora Therapeutics, Inc. | A method for reducing the likelihood of implantation failure in a subject |
| RU2271817C1 (ru) * | 2004-08-18 | 2006-03-20 | ЗАО "РеМеТэкс" | Биотрансплантат и способ лечения легочной гипертензии |
| ATE519109T1 (de) * | 2004-12-21 | 2011-08-15 | Univ Yale | Präeklampsie-diagnose |
| PL2548951T3 (pl) | 2006-03-23 | 2016-08-31 | Pluristem Ltd | Sposoby ekspansji komórek oraz zastosowania w terapii komórek i pożywek kondycjonowanych wytworzonych w ten sposób |
| US20110293583A1 (en) | 2006-03-23 | 2011-12-01 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
| US20110171182A1 (en) | 2006-03-23 | 2011-07-14 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
| CN101558151B (zh) * | 2006-03-23 | 2015-10-21 | 普拉里斯坦有限公司 | 细胞扩增方法和藉此产生的细胞和条件培养基用于治疗的用途 |
| KR101738323B1 (ko) | 2007-09-19 | 2017-05-19 | 플루리스템 리미티드 | 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도 |
| EP2303293A1 (en) | 2008-05-27 | 2011-04-06 | Pluristem Ltd. | Methods of treating inflammatory colon diseases |
| WO2010017378A2 (en) * | 2008-08-08 | 2010-02-11 | Indiana University Research And Technology Corporation | Methods and compositions for vasculogenic potential determination |
| WO2010026573A1 (en) | 2008-09-02 | 2010-03-11 | Pluristem Ltd. | Methods of selection of cells for transplantation |
| SG190659A1 (en) | 2008-09-02 | 2013-06-28 | Pluristem Ltd | Adherent cells from placenta tissue and use thereof in therapy |
| WO2010026574A2 (en) | 2008-09-02 | 2010-03-11 | Pluristem Ltd. | Adherent cells from placenta tissue and use thereof in therapy |
| CN105021821B (zh) * | 2008-10-31 | 2018-05-11 | 耶鲁大学 | 先兆子痫检测和治疗的方法和组合物 |
| CN102282252B (zh) * | 2008-11-19 | 2017-07-04 | 人类起源公司 | 羊膜来源的贴壁细胞 |
| CA2776882A1 (en) * | 2009-10-06 | 2011-04-14 | The Cohen Mcniece Foundation | Preparation and use of stromal cells for treatment of cardiac diseases |
| ES2553712T3 (es) | 2009-11-30 | 2015-12-11 | Pluristem Ltd. | Células adherentes de la placenta y uso de las mismas en el tratamiento de enfermedad |
| US20130039892A1 (en) | 2010-04-23 | 2013-02-14 | Pluristem Ltd. | Adherent stromal cells derived from plancentas of multiple donors and uses thereof |
| WO2011147967A1 (en) | 2010-05-27 | 2011-12-01 | Georg Duda | Skeletal muscle regeneration using mesenchymal stem cells |
| KR20190114045A (ko) * | 2010-12-17 | 2019-10-08 | 안트로제네시스 코포레이션 | 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료 |
| US20140017209A1 (en) | 2011-03-22 | 2014-01-16 | Pluristem Ltd. | Methods for treating radiation or chemical injury |
| US9657266B2 (en) | 2011-04-15 | 2017-05-23 | Pluristem Ltd. | Methods and systems for harvesting cells |
| ITTO20111183A1 (it) * | 2011-12-21 | 2013-06-22 | Univ Degli Studi Torino | Mezzo condizionato ottenuto da cellule staminali mesenchimali placentari e suo uso nel trattamento terapeutico della preeclampsia |
| SI2739720T1 (sl) | 2012-09-06 | 2015-04-30 | Pluristem Ltd. | Naprave in postopki za gojenje celic |
| EP2914104B1 (en) | 2012-10-31 | 2020-04-29 | Pluristem Ltd. | Method and device for thawing biological material |
| US10351910B2 (en) | 2013-02-20 | 2019-07-16 | Pluristem Ltd | Gene and protein expression properties of adherent stromal cells cultured in 3D |
-
2013
- 2013-08-31 US US14/425,960 patent/US9950014B2/en active Active
- 2013-08-31 HK HK16100329.4A patent/HK1212239A1/xx unknown
- 2013-08-31 SG SG10201700435XA patent/SG10201700435XA/en unknown
- 2013-08-31 SG SG11201501065QA patent/SG11201501065QA/en unknown
- 2013-08-31 WO PCT/IB2013/058186 patent/WO2014037863A1/en not_active Ceased
- 2013-08-31 EP EP13776574.9A patent/EP2892542B1/en active Active
- 2013-08-31 JP JP2015530529A patent/JP6371286B2/ja not_active Expired - Fee Related
- 2013-08-31 AU AU2013311289A patent/AU2013311289B2/en not_active Ceased
- 2013-08-31 CA CA2882687A patent/CA2882687A1/en not_active Abandoned
- 2013-08-31 CN CN201380046256.XA patent/CN104768559B/zh not_active Expired - Fee Related
- 2013-08-31 KR KR1020157005124A patent/KR101921787B1/ko not_active Expired - Fee Related
-
2015
- 2015-03-03 IL IL23752815A patent/IL237528B/en active IP Right Grant
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116747212A (zh) * | 2023-07-04 | 2023-09-15 | 山东省妇幼保健院 | 6-姜酚在制备治疗先兆子痫药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150216907A1 (en) | 2015-08-06 |
| KR20150047503A (ko) | 2015-05-04 |
| EP2892542B1 (en) | 2018-04-04 |
| HK1211242A1 (en) | 2016-05-20 |
| IL237528B (en) | 2019-11-28 |
| JP6371286B2 (ja) | 2018-08-08 |
| WO2014037863A1 (en) | 2014-03-13 |
| US9950014B2 (en) | 2018-04-24 |
| IL237528A0 (en) | 2015-04-30 |
| SG11201501065QA (en) | 2015-03-30 |
| AU2013311289B2 (en) | 2017-11-16 |
| CN104768559B (zh) | 2019-01-22 |
| AU2013311289A1 (en) | 2015-03-05 |
| SG10201700435XA (en) | 2017-02-27 |
| JP2015532656A (ja) | 2015-11-12 |
| EP2892542A1 (en) | 2015-07-15 |
| HK1212239A1 (en) | 2016-06-10 |
| KR101921787B1 (ko) | 2018-11-23 |
| CN104768559A (zh) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2892542B1 (en) | Methods for prevention and treatment of preeclampsia | |
| US10722541B2 (en) | Methods for treating radiation or chemical injury | |
| EP2626417B1 (en) | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy | |
| Woidacki et al. | Mast cells as novel mediators of reproductive processes | |
| US20110293583A1 (en) | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy | |
| US20110171182A1 (en) | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy | |
| US20140017209A1 (en) | Methods for treating radiation or chemical injury | |
| US20110256108A1 (en) | Methods of selection of cells for transplantation | |
| JP7082372B2 (ja) | 肺線維症治療剤、ｐｔｐｒｒ発現促進剤及び肺線維症治療用キット | |
| Abuwala et al. | Endometrial stem cells: origin, biological function, and therapeutic applications for reproductive disorders | |
| JP2024023760A (ja) | 間葉系幹細胞及び神経障害治療剤 | |
| CN110721196A (zh) | 蜕膜nk细胞及其细胞亚群来源外泌体在制备不孕不育相关疾病药物及辅助治疗剂中的用途 | |
| Hou et al. | Mesenchymal stem cells: opening a new chapter in the treatment of gynecological diseases | |
| HK1211242B (zh) | 用於预防和治疗先兆子痫的方法 | |
| AU2017373862A1 (en) | Treatment of lymphedema and related conditions using placental adherent cells | |
| HK1187950B (en) | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy | |
| HK1177759B (en) | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy | |
| HK1188812A (en) | Methods for treating radiation or chemical injury | |
| HK1188812B (en) | Methods for treating radiation or chemical injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190903 |